naturalX Ventures funding news – naturalX Ventures Announce Final Close of €100M VC Fund
Feb 17, 2025 | By Kailee Rainse

naturalX Ventures has closed a €100M VC fund to support consumer health startups. The fund aims to fill a gap in Europe’s healthcare investment landscape, primarily targeting Series A investments, but also open to late Seed and Series B rounds.
SUMMARY
- naturalX Ventures has closed a €100M VC fund to support consumer health startups.
- naturalX is backed by Schwabe Group, a global leader in plant-based pharmaceuticals.
Initial investments will range from €3-5M, with follow-up funding of up to €10M per company. Itwill act as a lead investor or co-investor, focusing mainly on European startups, with some investments in North America.
Read also - Pixel Photonics funding news – Munster-based DeepTech Startup Pixel Photonics Secures €1 Million in Funding
The fund focuses on the intersection of wellness and medicine, supporting science-backed products and services. They have already made investments in companies like mybacs, Flow Neuroscience, Kyan Health, and Meela, and have also invested in other healthcare-focused VC funds.
RECOMMENDED FOR YOU

[Funding alert] London-based Wagestream Secures €20.4 Million in Funding
Team SR
Apr 18, 2024

TEKEVER funding news – Lisbon-based TEKEVER has Secured €70 Million in Funding
Kailee Rainse
Nov 21, 2024
Marvin Amberg, founder of naturalX Health Ventures said, "I am very excited to double down on our thesis with the official launch of naturalX. The consumer health space has been overlooked by investors. We see an inflection point in Europe now, as consumers are finally taking more charge of their own health. Startups in the space need a partner with a shared vision, We analysed the U.S. health market and in many successful startups, the consumer is already at the centre. Our thesis is that this is just the beginning, and the European market will develop in a similar pattern. While we are starting to see some examples of consumer-focused healthcare companies in Europe reaching meaningful scale and significant funding, such as Oura or Neko Health, we think this market deserves more attention."
Carl-Philipp von Polheim, Founder of mybacs, a DTC probiotic subscription startup said, “naturalX led our Series-A round and has been an exceptional partner, bringing not only capital but also invaluable knowledge of the nutritional supplement and broader consumer health market. Their pragmatic, fast decision-making allows us to focus on growing our business,".
About naturalX
naturalX is backed by Schwabe Group, a global leader in plant-based pharmaceuticals. The name "natural" reflects their partner's heritage. naturalX was created to combine the best of natural health and digital health, blending traditional practices with modern innovations.